BCR and chronic myelogenous leukemia, BCR-ABL1 positive: <h4>Background</h4>BCR-ABL1 fusion proteins contain constitutively active tyrosine kinases that are potential candidates for targeted therapy with tyrosine kinase inhibitors such as imatinib in chronic myeloid leukemia (CML).